AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Acute myeloid leukemia (AML) pathogenesis driven by the AML1/ETO (A/E) fusion protein without mutations is not fully understood.
• Hypoxia-inducible factor 1α (HIF1α) is frequently overexpressed in A/E-positive AML and correlates with poor prognosis.

Purpose of the Study:

• To elucidate the role of A/E and HIF1α interaction in AML leukemogenesis.
• To investigate the therapeutic potential of targeting the A/E-HIF1α axis.

Main Methods:

• Investigated A/E and HIF1α interactions in AML cell lines and patient samples.
• Utilized in vitro proliferation assays and in vivo mouse models of leukemia.
• Analyzed gene expression, DNA methylation patterns, and therapeutic interventions.

Main Results:

• A/E and HIF1α co-expression enhances leukemia cell proliferation and disease severity.
• The A/E-HIF1α complex upregulates DNMT3a, leading to DNA hypermethylation and silencing of p15(INK4b).
• Targeting the A/E-HIF1α loop reverses DNA methylation, reactivates tumor suppressors, and inhibits leukemia growth.

Conclusions:

• HIF1α is a crucial cofactor for A/E in driving AML progression.
• The A/E-HIF1α interaction creates a therapeutic vulnerability in high-risk AML.
• HIF1α serves as a prognostic marker and a potential therapeutic target for A/E-driven AML.